You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Primum non nocere: is faecal microbiota transplantation doing harm to patients with IBS?
  1. Paul Enck
  1. Department of Internal Medicine VI: Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Tübingen, Germany
  1. Correspondence to Professor Paul Enck, Department of Internal Medicine VI: Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Tuebingen, Germany; paul.enck{at}uni-tuebingen.de

https://doi.org/10.1136/gutjnl-2018-317277

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A recent paper in this journal1 caught my attention: In a well-designed placebo-controlled trial of faecal microbiota transplantation (FMT) in patients with IBS, 12 days of blinded provision of the transplant or placebo in capsules improved symptoms in patients randomised to placebo significantly better than in patients receiving FMT, for IBS symptom severity at 3 and 6 months, and for IBS quality of life at 1, 3 and 6 months of follow-up. Patients receiving FMT showed sustained alterations of their microbiota, obviously unrelated to the symptom burden.

    Taking the effect of FMT on the gut microbiota in IBS aside (that has a scientific value by itself), these results not only imply that improvements seen with FMT in IBS in controlled2 …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.